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reported and the mean calculated wKt/V and wCCr were 2.3 Clinical performance measures: The changing status of perito-
0.6 and 72.7  24.9 liters/1.73 m2/week for CAPD patients andneal dialysis.
2.3  0.6 and 71.6  25.1 L/1.73 m2/week for APD patients.Background. The Peritoneal Dialysis–Clinical Performance
PD subjects had a mean body weight of 76  19 kg and bodyMeasures Project (PD-CPM) characterizes peritoneal dialysis
mass index (BMI) of 27.5  6.4 kg/m2. The protein equivalentwithin the U.S. Current survey results are reported and com-
pared to those of previous years. of nitrogen appearance (nPNA) of these patients was 0.95 
Methods. Prevalence data from random national samples 0.31 g/kg/day, their normalized creatinine appearance rate
of adult peritoneal dialysis (PD) patients participating in the (nCAR) equaled 17  6.5 mg/kg/day, resulting in a percent
United States End-Stage Renal Disease (ESRD) program have lean body mass (%LBM) of 64  17% of actual body weight.
been collected annually since 1995. Serum albumin correlated in a positive fashion with BMI,
Results. In 1995, 79% of the respondents used continuous nPNA, nCAR and %LBM, but not with wCCr.
ambulatory peritoneal dialysis (CAPD) rather than automated Conclusions. The majority of indicator variables monitored
peritoneal dialysis (APD). The mean hematocrit (Hct) of PD by the PD-CPM have improved since 1995. PD patients have
patients was 32% and only 66% of individuals had a measure- higher hemoglobins and a greater proportion of patients meet
ment of dialysis adequacy reported. The mean weekly Kt/Vurea the criteria for adequate dialysis. Serum albumin values, how-
(wKt/V) and weekly creatinine clearance (wCCr) reported for ever, remain marginal and unchanged over the five-year project.
CAPD patients in 1995 were 1.9 and 67 L/1.73 m2/week, respec- Furthermore, serum albumin values fail to correlate with the
tively. In 2000 the median age of PD patients was 55 years and intensity of renal replacement therapy and are not strongly
63% were white. The leading cause of ESRD was diabetes correlated with alternative estimates of nutritional status.
mellitus (34%) and 54% of adult PD patients performed some
form of APD rather than CAPD. Age, sex, size, hematocrit,
peritoneal permeability, dialysis adequacy, residual renal func-
tion and nutritional indices did not differ between APD and The Centers for Medicare and Medicaid Services (CMS),
CAPD patients. The mean hemoglobin (Hb) for the 2000 PD- formerly the Health Care Financing Administration
CPM population was 11.6  1.4 g/dL (mean  1 SD) and 11% (HCFA), initiated the Peritoneal Dialysis–Core Indica-of patients had an average Hb below 10 g/dL. The average
tors Study (PD-CIS) in 1995 [1]. The study’s plannersserum albumin was 3.5  0.5 g/dL by the bromcresol green
believed that improvements in patient care would bemethod and 56% of subjects had an average serum albumin
equal to or above 3.5 g/dL (or 3.2 g/dL by bromcresol purple). more likely if the traditional “case review” process was
In 2000 85% of patients had a dialysis adequacy measurement replaced by a population-based quality assurance pro-
gram using statistical outcomes. It was proposed that
combining appropriate data collection with the timely1 Note: The Centers for Medicare and Medicaid Services (CMS), for-
merly the Health Care Financing Administration (HCFA) ESRD Core presentation of “benchmark results” and professional
Indicators Study, supplied the data described in this report. The inter- education would improve both the quality of dialysispretation and reporting of these data are the responsibility of the
services and patient welfare [2–5]. The PD-CIS Work-authors and are not an official policy or interpretation of the Centers
for Medicare and Medicaid Services. group subsequently identified several measurable “key”
indicators of dialysis performance and patient outcome,Key words: CAPD, cycler dialysis, 1998 PD-CIS, solute clearance, ade-
quacy of dialysis. and initiated a sampling methodology to assess the state
of peritoneal dialysis therapy within the U.S. From 1995
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was incorporated into the Peritoneal Dialysis–Clinical Results are presented as mean  1 standard deviation
(SD) unless otherwise stated. Comparisons were consid-Performance Measures (PD-CPM) project [1]. The pres-
ent status and recent trends in several key indicators of ered significant if the two-tailed P value corrected for
multiple comparisons was below 0.05.peritoneal dialysis are presented in this study.
METHODS RESULTS
In 2000 clinical information was collected for 1603In the spring of each survey year the 18 Regional
ESRD Networks provide CMS with a listing of PD pa- adult patients, 50% male, 63% white and 27% black,
with a median age of 55 years (mean  1 SD, 54.9 tients within their geographic area. This list is used to
select a random cohort of patients large enough to allow 15.0 years). As evident in Table 1, the leading causes
of ESRD were diabetes mellitus (34%), hypertensionestimation of an age proportion with a 95% confidence
interval around those estimates no larger than 10 per- (21%), and glomerulonephritis (19%). In the 1995 sur-
vey, the median dialysis experience of PD patients wascentage points (that is, 5%). This consists of approxi-
mately 5% of the adult (18 years of age) U.S. PD 1.4 years (mean  1 SD, 2.4  3.0 years; 25th to 75th
percentiles, 0.53 to 2.94 years), and 79% of patients per-population who are alive and performing peritoneal dial-
ysis on December 31 of the preceding year. Subse- formed CAPD while 21% used automated or cycler peri-
toneal dialysis (APD). In 1998 the median dialysis expe-quently, a questionnaire is distributed to the dialysis fa-
cility providing care for each of the selected subjects. rience of PD patients was 1.8 years (mean 1 SD, 2.9
3.5 years, 25th to 75th percentiles 0.60 to 3.60 years) andFacility staff abstract clinical information from the pa-
tient’s medical record for each subject receiving perito- 55% of patients performed CAPD, while in 2000 the
median dialysis experience of PD patients was 1.6 yearsneal dialysis at any time during the six months preceding
the sample selection. Completed questionnaires are for- (mean  1 SD, 2.8  3.5 years, 25th to 75th percentiles
0.66 to 3.62 years) and only 46% of patients used CAPDwarded to regional End-Stage Renal Disease (ESRD)
Network Offices for data verification and electronic sub- while 54% used APD as their predominant dialysis mod-
mission to CMS. The data contained in these reports ality. APD and CAPD patients differed significantly only
are identified as the PD-CIS and PD-CPM prevalence in the daily dialysate volume (outflow volumes: APD,
surveys for the years 1995 to 2000. Validation studies 187 51 mL/kg/day or14 L/day; CAPD, 149 43 mL/
have been conducted for each collection period. The kg/day or 11 L/day). Earlier surveys found no differ-
latest study reported the mean level of concurrence be- ences in height, gender, the cause of ESRD, duration
tween facility reported and independent reviewer ab- of time on dialysis, peritoneal equilibrium test (PET)
stracted data to be 0.87  0.06 [6], with kappa statistics permeability, residual renal function, or dialysis ade-
between 0.67 and 1.0 for the data analyzed herein. quacy between APD and CAPD patients [9]. These simi-
The data collected included information about patient larities continue in the PD-CPM 2000 survey, with the
demographics, the dialysis prescription, dialysis dose, re- exception of a minimally greater wKt/V for APD pa-
sidual renal function, anemia management, and serum tients (wKt/V 2.34  0.60 for APD and 2.27  0.56
albumin. The body mass index (BMI) as kg/m2 of height, for CAPD patients, P  0.02 by paired t test). Table 1
total renal plus dialysis weekly fractional urea clearance illustrates that the U.S. PD population has been rela-
(wKt/Vurea) or (wKt/V), total weekly renal glomerular tively stable in composition between 1995 and 2000, but
filtration rate (GFR) plus dialysate creatinine clearance PD patients remain a select sub-group of the dialysis
(wCCr) as liters/1.73 m2/week, protein equivalent of nitro- population. PD patients are younger, less likely to have
gen appearance (nPNA) in mg/kg/day, creatinine ap- diabetes or hypertension as the cause of renal failure, and
pearance rate (nCAR) in mg/kg/day, and percent lean more likely to be white than are in-center hemodialysis
body mass (%LBM) as a percent of actual body weight patients.
were calculated in a standard fashion [7, 8], and when ap-
Anemia managementpropriate normalized to standard body weight and surface
area using the Watson total body water and DuBois and The mean hemoglobin (Hb) for PD patients in the
PD-CPM 2000 survey was 11.6  1.4 g/dL (25th to 75thDuBois or Gehan body surface area calculations [8].
Statistical analyses including descriptive statistics, t tests, percentiles, 10.8 to 12.4 g/dL) and only 11% of subjects
had a Hb 10 g/dL. Seventy-six percent of the PD pa-analysis of variance (ANOVA), linear regression models
and correlations have been conducted using the com- tients had an average serum ferritin100 ng/mL (mean,
399  408 ng/mL) and 74% a transferrin saturationputer software packages Microsoft Excel v 5.1 (Micro-
soft Corp, Redmond, WA, USA) for the MacIntosh 20% (mean, 29%  13%). Erythropoietin (rHuEPO)
was administered to 89% of PD patients at some time(Apple Computer, Cupertino, CA, USA), and SPSS re-
lease 9.0 for Windows (SPSS Inc, Chicago, IL, USA). during the six-month survey; 98% of the subjects re-
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Table 1. Patient demographics
Peritoneal dialysis Hemodialysis
Characteristic 1995 1996 1997 1998 1999 2000 2000
Sample size - N 1202 1208 1219 1381 1533 1603 8154
Male % 640 (53) 654 (54) 626 (51) 698 (51) 760 (50) 808 (50) 4336 (53)
Race
White 814 (68) 775 (64) 795 (66) 838 (61) 928 (61) 1006 (63) 4444 (55)
Black 304 (25) 318 (26) 297 (25) 389 (28) 404 (26) 429 (27) 2985 (36)
Asian/Pacific 40 (3) 48 (4) 17 (1) 55 (4) 56 (4) 81 (5) 334 (4)
Native American 18 (2) 16 (1) 2 (0.2) 15 (1) 34 (2) 18 (1) 155 (2)
Other 26 (2) 49 (4) 94 (8) 76 (6) 111 (7) 69 (4) 263 (3)
Ethnicity
Hispanic 115 (9) 136 (10) 152 (10) 173 (11) 980 (12)
Age group
18–44 352 (29) 336 (28) 332 (27) 384 (28) 402 (26) 423 (26) 1399 (17)
45–64 481 (40) 500 (41) 551 (45) 589 (43) 687 (45) 730 (45) 3074 (38)
65 369 (31) 372 (31) 336 (28) 403 (29) 444 (29) 450 (28) 3681 (45)
Diagnosis
Diabetes mellitus 385 (32) 414 (34) 421 (34) 496 (36) 505 (33) 545 (34) 3258 (40)
Hypertension 309 (26) 266 (22) 270 (22) 286 (21) 332 (22) 338 (21) 2103 (26)
Glomerulonephritis 271 (23) 217 (18) 216 (18) 232 (17) 299 (20) 306 (19) 1006 (12)
Other/unknown 237 (20) 308 (26) 312 (26) 351 (26) 397 (26) 414 (26) 1787 (22)
Modality
CAPD 931 (79) 796 (66) 757 (59) 804 (55) 762 (55) 646 (46)
APD 247 (21) 402 (34) 521 (41) 663 (45) 626 (45) 745 (54)
Residual GFR mL/min 4.99.1 3.55.9 3.23.2 3.43.4 3.83.5 4.34.1
Median GFR 2.7 2.4 2.4 2.4 2.9 3.3
Patients who use peritoneal dialysis differ from center hemodialysis patients, they are younger, more likely to be white, and less likely to have their end-stage
renal disease (ESRD) attributed to diabetes mellitus or hypertension. Additionally, the proportion of PD patients using automated peritoneal dialysis (APD) rather
than continuous ambulatory peritoneal dialysis (CAPD) continues to increase. The comparison hemodialysis population is reported by the 2000 Hemodialysis–Clinical
Performance Measures Study (2000 HD-CPM).
ceived the drug via subcutaneous injection and the aver- dent correlative strength, and more than 90% of the
age weekly rHuEPO dose was 51  41 U/kg (25th to 75th predictive information was provided by gender, residual
percentiles, 23 to 66 U/kg/week). Sixty-nine percent of GFR and nCAR. In general the rHuEPO dose fell with
PD patients had a mean Hb 11 g/dL, but only 36% of increasing residual GFR, older age, increasing albumin,
rHuEPO-treated PD patients had a mean Hb within and male sex. rHuEPO doses increased as the lean body
the DOQI target range of 11 to 12 g/dL. This occurred mass increased. Fewer than 1% of rHuEPO treated sub-
because 36% of rHuEPO-treated PD patients had a jects received more than 250 units of rHuEPO per kilo-
mean Hb below 11 g/dL and 30% a mean Hb above gram of body weight weekly.
12 g/dL. The number of patients treated with rHuEPO
Blood pressure controlhas increased since 1995 (Fig. 1). Concurrently the mean
hematocrit (Hct) increased from 32.5% in 1995 to 11.6 Clinic blood pressures are not reported in the PD-
g/dL (Hct 34.8%) in 2000 and the prevalence of pa- CPM survey but were collected by the Peritoneal Dial-
tients with a Hct 30% has declined from 36% in 1995 ysis–Clinical Indicators Studies (PD-CIS) of 1995 to 1998.
to the current findings in which only 11% of subjects There was a consistent, albeit modest, fall in the num-
have a mean Hb 10 g/dL. In 2000 only 4% of all PD ber of patients with a systolic BP greater than 150 mm Hg
patients had a Hb value 9 g/dL. The likelihood of over that four-year interval. The mean six-month aver-
rHuEPO therapy was inversely proportional to the Hb, age systolic and diastolic blood pressures were 136.6 
as 92% of subjects not treated with rHuEPO had a Hb 20.2 mm Hg and 79.4  12.0 mm Hg, respectively, for
10 g/dL while 83% of PD patients with a Hb 10 g/dL 1998 PD-CIS subjects, and remain unchanged from 1995.
were treated with rHuEPO. Similarly, the prescribed In 1998 only 23% of subjects had a systolic BP150 mm
rHuEPO dose correlated inversely with the Hb: Hg, and a diastolic BP 90 mm Hg was reported in 16%
of subjects; these numbers are reduced from the respec-rHuEPO dose (U/kg/week)
tive 29% and 18% prevalences in 1995.
 164 U/kg/week  9.9  (Hb) (Eq. 1)
Dialysis adequacywhere r  0.31 and P  0.001.
In 1998 72% of the returned questionnaires containedThe rHuEPO dose (U/kg/week) also correlated with
enough data for an independent calculation of a wKt/V,several non-“iron status” characteristics, but only gen-
der, residual GFR, nCAR, albumin and age had indepen- and in 2000 this increased to 82%. The dialysis adequacy
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Fig. 1. Peritoneal dialysis (PD) indicators from 1995 to 2000. There have been progressive increases in the number of PD patients treated with
erythropoietin (Epoetin or rHuEPO), the hemoglobin achieved (Hb), and the number of patients with a measured dialysis delivery since the
inception of the ESRD Core Indicators/Clinical Performance Measures Project. Among patients with a reported weekly dialysis dose (wKt/V)
measurement, the frequency of achieving minimal DOQI adequacy criteria has increased from 23% in 1995 to 63% in 2000. While 85% of subjects
have a measurement of dialysis delivery reported, 18% of the reports do not contain complete adequacy measurement data. Thus, adequate dialysis
delivery can be validated for only 62% of all PD subjects (a value increased from 27% in 1996 and 44% in 1998). Additionally, the average systolic
blood pressure fell during a 4-year observation period. Despite these changes, serum albumin values have not changed since 1995, and the mean
average serum albumin remains 3.5  0.5 g/dL. Note: hemoglobin values for the years 1995 to 1997 are approximated from hematocrit values
(Hb  Hct/3), and blood pressure data were not collected in years 1999 and 2000.
Fig. 2. Calculated and reported dialysis ade-
quacy values. The dialysis adequacy measure-
ments, weekly dialysis dose (wKt/V) and weekly
creatinine clearance (wCCr), reported by dial-
ysis facilities generally agree with values calcu-
lated from the raw data (r2  0.80). Modest
variations about unity may be methodological
(that is, multiple normalization formulae are
permitted for calculating body surface area
and urea distribution volume), or technical
(that is, the ability to accurately obtain, trans-
mit and use the data in all the necessary data
fields). It is likely that technical difficulties
result in larger variances.
indices were calculated in accord with DOQI guidelines Calculated wKt/V
 1.01  (Facility reported wKt/V) (Eq. 2)and normalized to the Watson standard body weight/
volume and the DuBois body surface area. Figure 2 where r2  0.96.
reveals that the calculated wKt/V and wCCr values were
Calculated wCCrnot significantly different from those reported by the
 0.85  (Facility reported wCCr) (Eq. 3)dialysis facilities (P  0.06 and 0.16, respectively, by
paired t test). where r2  0.80.
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Fig. 3. Deviation of calculated from reported
dialysis adequacy. The relative deviation be-
tween facility-reported and calculated wKt/V
and wCCr data are represented as the percent
difference between the facility reported and
the calculated values [100%  (calculated 
reported)/calculated]. More than 80% of paired
wKt/V values were within 10% of one another:
10th and 90th percentiles 4.1% and 6.3%,
respectively. Alternatively, 10% of reported
wKt/V values deviate by more than 10% from
the calculated value. Calculated values are de-
rived from “crude” clearance data supplied by
the facility. The deviation of the calculated
wCCr from the facility reported wCCr values
exceeds that of the wKt/V measurements (10th
and 90th percentiles, 18.9% and 0.9%, re-
spectively), and while there does not appear
to be a systematic bias in wKt/V reporting,
facilities tend to overestimate wCCr values. Ex-
planations for the wCCr discrepancies are more
likely technical than methodological (that is,
it is unlikely that this represents a difference in
the normalization technique used, but rather a
failure to adjust residual renal function to a GFR
estimate rather than a creatinine clearance).
The deviations between the facility reported and the mean serum albumin value for PD patients did not
change appreciably since 1995, and in 2000 the meancalculated wKt/V and wCCr values are shown in Figure 3.
Fewer than 20% of the dialysis facility reported wKt/V serum albumin values were 3.5  0.5 g/dL by BCG and
3.3  0.6 g/dL by BCP. Fully 44% of PD patients hadvalues vary more than 10% from the paired calculated
value, and this variation is likely due to different methods an average albumin value below the 3.5 g/dL (or 3.2 g/dL
by BCP), which the DOQI guidelines consider desirableused by facilities to calculate the V.
In 2000, the mean facility reported wKt/V and wCCr [8]. In 2000 the serum albumin values were lower in
patients with diabetes as the cause of their renal diseasevalues were 2.3 0.6 and 75.9 32.4 liters/1.73 m2/week,
respectively. The wCCr values reported for CAPD and (3.38  0.50 g/dL) than in patients with other causes of
ESRD (3.55  0.51 g/dL), in females (3.44  0.48 g/dL)APD patients were not significantly different from one
another (P  0.30), while the wKt/V values of APD compared to males (3.54  0.51 g/dL), and serum albu-
min values were inversely related to indices of dialysispatients exceeded those of CAPD patients (APD 2.34,
CAPD  2.27; t test, P  0.02). Sixty-two percent of intensity (wCCr), patient age, and duration of dialysis
experience. In prior years serum albumin has been in-patients had a mean calculated wKt/V measurement that
met or exceeded DOQI adequacy guidelines (wKt/V versely correlated with peritoneal permeability (4-hour
D/P creatinine ratio by PET testing) and the dialysis2.0 for CAPD or wKt/V 2.1 for APD). Similarly,
66% of subjects with a facility reported wKt/V met or component of wCCr (wdCCr).
In 2000 the mean body weight of PD patients was 76exceeded the DOQI guidelines for dialysis adequacy.
Figure 4 illustrates the increases in calculated mean dial- 19 kg and the mean body mass index (BMI) was 27.5 
6.4 kg/m2. Dialysis adequacy data were used to deriveysis adequacy values since 1995. The dose of dialysis
provided from peritoneal dialysis alone increased 10 mL/ mean values for the protein equivalent of nitrogen ap-
pearance (nPNA  0.95  0.31 g/kg/day), normalizedmin for wCCr and 0.5 units for wKt/V from 1995 to 1998,
but has not increased further in the latest two years of creatinine appearance (nCAR  17  6.5 mg/kg/day)
and lean body mass (%LBM  64%  17% of actualobservation. The sequential increases in mean wKt/V and
wCCr values achieved by PD patients during the five-year body weight). Serum albumin continued to correlate in
a positive fashion with lean body mass, body mass index,data collection period can be attributed to both increased
dialysis delivery and greater residual renal function. nPNA and nCAR, but not with wCCr [7]. While the Peri-
toneal Equilibration Test (PET) results are not available
Nutritional indicators for the years 1999 and 2000 at this writing, the serum
albumin values previously had been negatively corre-Dialysis patient serum albumin values differ systemati-
cally with the laboratory assay used, and the bromcresol lated with the D/P creatinine results [11]. The correlation
coefficients, or r values, for the above relationships weregreen (BCG) method continues to yield higher values
than the bromcresol purple (BCP) method [10]. The generally less than or equal to 0.2.
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Fig. 4. Peritoneal delivery from 1995 to 2000. There has been an increase in the dialysis adequacy indices achieved by peritoneal dialysis patients
since 1995. Calculating the weekly Kt/Vurea (wKt/V) and total weekly creatinine clearance (wCCr) values as suggested by the National Kidney
Foundation Dialysis Outcomes Quality Initiative (DOQI), the mean wKt/V delivered to adult PD patients has increased from 1.9 in 1995 to 2.3
in 2000. Similarly, the calculated wCCr values increased from a mean of 61.5 L/1.73 m2/week to 72 L/1.73 m2/week. This is partially a result of the
greater residual renal function noted in the PD-CPM 2000 survey group (P  0.036). The mean dialysis contributions to the weekly urea and
creatinine clearances are illustrated by the wdKt/V and wdCCr values and have not changed in the last three years.
DISCUSSION There has been a progressive reduction in the presence
of severe anemia and a steady increase in the mean HbThe number of U.S. residents using PD continues to
of chronic peritoneal dialysis patients during the lastincrease, and in 1999 CMS’s Facility Survey indicated
three years. The percentage of patients with a Hct valuethat 30,673 Medicare recipients (16% of the U.S. dialysis
greater than 30% has increased from 63% in 1995 topopulation) used PD to manage their ESRD [12]. The
approximately 89% in 2000 (Hb 10 g/dL). If associa-2000 Peritoneal Dialysis – Clinical Performance Mea-
tions between Hb and patient mortality and morbidity aresures Study is a cross-sectional prevalence survey de-
causal and consistent across dialysis modalities [15, 16],picting the status of these patients and presents an oppor-
these changes should effect profound improvements intunity to inspect trends in U.S. dialysis practices. APD
patient well-being. The Hb increases of PD patients havecontinues to gain popularity, and in 2000 almost equal
coincided with an increasing reliance upon rHuEPO. Innumbers of patients used CAPD and APD. The major dif-
1995, 73% of surveyed PD patients had prescriptions forference between these two groups continues to be that
rHuEPO, and this increased to 85% in 1998 and 89%APD patients use 25% more dialysis fluid to achieve equal
in 2000. Both the likelihood of rHuEPO treatment anddialysis adequacy measures, nutrition (nPNA, LBM, se-
the rHuEPO dose vary inversely with the severity of ane-rum albumin), hematocrit, and blood pressure control
mia. Presently, the average rHuEPO dose for a PD patient[7, 10, 13]. Since the CAPD and APD populations do
is 51 U/kg/week and 99% of all PD patients are prescribednot vary substantially in age, sex, size, peritoneal perme-
less than 250 U/kg/week. Thus, while rHuEPO depen-ability, dialysis adequacy or nutritional indices, they are
dence is common, rHuEPO resistance is unusual. Therecombined into a single PD population for the remainder
are multiple differences between PD and hemodialysisof the discussion.
patients, but the most plausible reason that rHuEPOThe PD population is a select subgroup of ESRD
resistance is uncommon among PD patients is that theypatients. PD patients are younger, less likely to have a
have less blood and iron loss as a consequence of therapy.primary diagnosis of diabetes mellitus or hypertension,
Future ESRD Clinical Performance Measures’ reportsand more likely to be white than are hemodialysis pa-
will review PD iron management and its impact upontients [14]. These characteristics have persisted over the
anemia control.last six years and suggest that patient allocation to perito-
In 1995 only 66% of PD patients had an assessmentneal and hemodialysis may be more closely related to
of dialysis adequacy and the calculated wKt/V deviatedsocioeconomic factors than to specific physiologic or dis-
ease characteristics. on average 15% from that reported by the dialysis
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center [17]. In 2000 85% of PD patients had at least ery, and anemia management, the serum albumin values
of adult U.S. PD patients have not improved.one, and 39% had two assessments of peritoneal dialysis
adequacy during the six-month survey period. Further, The PD-CPM project was undertaken to better define
the status of U.S. adult peritoneal dialysis patients andthe reliability of the facility-reported wKt/V and wCCr
values has improved. In 2000, when the both the facility- to provide information for provider quality improvement
efforts. The practice of PD has changed substantiallyreported and calculated dialysis adequacy values were
present, the relative variability of the reported wKt/V since the inception of the PD-CIS/PD-CPM [18]. More
patients use automated delivery systems and larger quan-and wCCr values from the calculated values was below
20% (10th and 90th percentiles for wKt/V and wCCr are: tities of dialysis fluid to achieve desirable dialysis indices.
Erythropoietin use has increased and fewer patients are4% to 6%; and 19% to 1%, respectively). This
suggests a relatively uniform data collection and pro- severely anemic. Most patients now have their dialysis
quantified and more patients meet the DOQI criteriacessing method resulting in standardized reporting of
dialysis delivery. Additionally, both the facility-reported for minimal dialysis adequacy. While the blood pressure
control of PD patients improved progressively betweenand calculated wKt/V and wCCr values are increasing.
The mean calculated wKt/V has increased from 1.8 in 1995 and 1998, subsequent data have not been collected.
Despite these changes there has been no demonstrable1995 to 2.3 in 2000. Calculated dialysis adequacy indices
document that 62% of subjects have a delivered dialysis improvement in the serum albumin values of PD pa-
tients, and changes in the clinical status, health and sur-dose fulfilling DOQI guidelines for wKt/V [8]. Thus,
while dialysis adequacy measures could not be indepen- vival of these patients have yet to be measured.
Dialysis practices and outcomes are gaining uniformitydently verified for 18% of PD patients, this report repre-
sents a remarkable evolution in PD practices [18]. The but substantial opportunities remain to improve the mea-
surement, delivery and outcome of peritoneal dialysis.Peritoneal Dialysis–Core Indicators Study/Clinical Per-
formance Measures Project has been a penalty free qual- During the last five years there has been an enormous
effort focused upon measuring processes believed to de-ity indicator tool for only five years and in that time,
20% more patients have a wKt/V measured, 80% of termine the health, survival and quality of life of PD
patients. Generally, the parameters monitored have im-wKt/V values are derived in a standard fashion, and the
delivered wKt/V has increased 20%. If each 0.1 unit proved, though the reliability and implications of these
changes remain unknown. Simple, direct measurementsincrease in delivered wKt/V above a value of 1.5 results
in a 5% improvement in patient survival, then these such as hemoglobin have inherent uncertainty as a result
of both the imprecision of laboratory measurements andchanges should result in improved longevity, health, and
quality of life for PD patients [19–24]. biological variability [33], but the values provided by
the dialysis facilities are reproducible based upon dataMalnutrition is reportedly common among dialysis pa-
tients [25–28], and both malnutrition and hypoalbumi- abstraction/validation studies. More complex measure-
ments, such as dialysis delivery, appear to result in addi-nemia, a presumed surrogate for poor nutrition, correlate
with the health of dialysis subjects [21, 29–32]. The aver- tional unpredictability. In the case of wKt/Vurea there is
a 8% coefficient of variation (SD/mean) for the differ-age serum albumin of the PD subjects surveyed in 2000
is 3.5  0.5 g/dL, a value on the low end of the normal ence between the calculated and the facility reported
wKt/Vurea value. This variation is likely due to differentrange. Further, while most parameters monitored by the
PD-CPM have improved progressively over the last five methods used by facilities to calculate V and attributable
to a DOQI methodology that permits multiple, non-years, there has been no discernable change in the serum
albumin values of PD patients. If a serum albumin below equivalent normalization processes. In 18% of cases,
however, wKt/Vurea could not be calculated because the3.5 g/dL indicates poor nutrition then 44% of PD patients
are malnourished, and malnutrition is most common crude data necessary to derive wKt/Vurea were unavail-
able and in 11% of cases the difference between theamong the elderly, women, and those with diabetes mel-
litus. Further, while the serum albumin is positively cor- calculated and the reported wKt/Vurea value was large
enough to consider the reported value to be an “outlier.”related with indices of body size (lean body mass, body
mass index) and dietary protein intake (nPNA), it ap- The situation is more complex for wCCr. While calcu-
lated and facility reported wCCr values differed with apears to decrease as dialysis delivery (wCCr) is increased.
Because serum albumin has been inversely correlated mean coefficient of variation of only 10%, there was
a determinant error or systematic overestimation of wCCrwith both PET test results and the dialysis-only compo-
nent of wCCr, this relationship is likely a result of in- by dialysis facilities. The deviation of the calculated wCCr
from the facility reported value increased in proportioncreased peritoneal albumin losses when elevated dialysis
delivery is a consequence of elevated membrane perme- to both the residual renal function (GFR) and wCCr (P
0.05), was most strongly correlated with the GFR (r ability. Albumin kinetics are complex and despite pro-
cess improvements in dialysis prescribing, dialysis deliv- 0.20, P 0.03), was unrelated to BSA normalization, and
Flanigan et al: PD-CIS 20002384
1997 ESRD Facility Survey, accessed June 9, 1999, web site http://was absent when patients had no residual renal function.
www.hcfa.gov/stats/pufiles.htm
This suggests that a substantial number of dialysis centers 13. Flanigan MJ, Rocco MV, Frankenfield DL, et al: 1996 Peritoneal
are not converting the residual renal creatinine clearance Dialysis-Core Indicators Report. Am J Kidney Dis 32:E3, 1998,
accessed June 9, 1999, web site http://www.ajkdjournal.org/index.into an estimated GFR before including it in the wCCr.
htmlFurthermore, there is disparity in how “adequate” dial- 14. Health Care Financing Administration: 1998 Annual Report:
ysis is attained. Some PD subjects have substantial resid- ESRD Core Indicators Project. Baltimore, Department of Health
and Human Services, Health Care Financing Administration, Of-ual renal function contributing to their overall wKt/V
fice of Clinical Standards and Quality, December 1998, web siteand wCCr, while others depend heavily upon dialysis urea http://www.hcfa.gov/quality/3h.htm.
and creatinine clearance (wdKt/V and wdCCr). This com- 15. Ma JZ, Ebben J, Xia H, Collins AJ: Hematocrit level and associ-
ated mortality in hemodialysis patients. J Am Soc Nephrol 10:610–bination of measurement uncertainty and physiologic
619, 1999non-equivalence will make it difficult to assess relation-
16. Xia H, Ebben J, Ma JZ, Collins AJ: Hematocrit levels and hospi-
ships between changing dialysis delivery and patient out- talization risks in hemodialysis patients. J Am Soc Nephrol 10:1309–
comes. It is likely that both further provider education 1316, 1999
17. Rocco MV, Flanigan MJ, Beaver S, et al: Report From the 1995and more specific measurement methodology will be re-
Core Indicators for Peritoneal Dialysis Study Group. Am J Kidneyquired before changes in indicator variables can be con- Dis 30:165–173, 1997
vincingly coupled to changes in patient outcome. During 18. Frankenfield DL, Prowant BF, Flanigan MJ, et al: Trends in
clinical indicators of care for adult peritoneal dialysis patients in thethe last five years there have been dramatic improve-
United States from 1995 to 1997. Kidney Int 55:1998–2010, 1999ments in most PD-CPM indicator values, but opportuni-
19. Genestier S, Hedelin G, Schaffer P, Faller B: Prognostic factors
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